Keynote speaker (first session)


Enjung (Alice) Lee, Ph.D. Harvard Medical School

Lee lab.

Alice is a faculty member of the Harvard Bioinformatics and Integrative Genomics (BIG) PhD Program. 

Her research group is aimed to characterize genomic variation and functional change associated with 

human disease using computational genomics and a bioinformatic approach.

Currently, we focus on investigating aberrations in repetitive DNA, particularly transposable elements,

and other types of genomic variants in various human diseases. We envision pioneering the frontiers

of knowledge on a human disease with the latest genomic technologies and rigorous computational

analyses ultimately translating our scientific discoveries into improved healthcare outcomes.

Keynote speaker (second session)


Namshik Han, Ph.D. 

Head of Computational Research & AI, Milner Therapeutics Institute, University of Cambridge

Associate Faculty, Cambridge Centre for AI in Medicine, Department of Applied Mathematics and Theoretical Physics, University of Cambridge

Co-founder, and CardiaTec Biosciences


I am a computational drug discovery scientist, coming from a background in machine learning, computational biology, cancer genomics and cancer epigenomics. I am Head of Computational Research & AI at Milner Therapeutics Institute in University of Cambridge and also Associate Faculty at Cambridge Centre for AI in Medicine in the same University. My lab develop and apply dedicated and bespoke Artificial Intelligence technologies that deal with the uncertainty and complexity of biological datasets to reveal novel disease pathways and mechanisms. I also have an Adjunct Professor position at Yonsei University College of Medicine. In addition to my academic research, I have a passion for working at the interface between academia and industry to apply my research to real-world problems. In my case this is in therapeutics and patient care where AI promises to revolutionize the ability to identify disease mechanisms and potential drug targets, informing patient care from disease diagnosis through to treatment. Towards this aim, I facilitate access of the Milner Therapeutics Consortium partner organizations to cutting-edge AI technology and to develop new computational methods fulfilling the global mission of identifying new or better therapies from the analysis of biological data. Furthermore, I contributed to the establishment of Storm Therapeutics. I co-founded two start-ups: (1) to develop immune-oncology NK cell therapy and (2) CardiaTec to develop innovative drugs for cardiovascular diseases.